Reports the Results of a Chemotherapy Trial for Peritoneal Mesothelioma

Share Article reports the results of a chemotherapy trial that investigated pemetrexed and gemcitabine for the treatment of peritoneal mesothelioma. has updated its Recent News blog with a report on a chemotherapy study that investigated the efficacy of combination chemotherapy using pemetrexed and gemcitabine for the treatment of peritoneal mesothelioma. Previous studies have shown that pemetrexed is among the most active chemotherapy agents for the treatment of mesothelioma and its use in combination therapy with cisplatin represents the chemotherapy standard of care for pleural mesothelioma. Gemcitabine is a commonly-used chemotherapy agent for a number of other forms of cancer.

20 patients with unresectable, histologically-confirmed peritoneal mesothelioma were enrolled in the study, although not all patients were able to complete the full treatment plan. The study concluded that pemetrexed and gemcitabine were active in the treatment of the disease, with the patient cohort under investigation demonstrating an overall survival figure of 26.8 months. However, the chemotherapy regimen also caused a high number of treatment effects in patients, so the authors of the study suggested that future trials should investigate the treatment at lower dosage levels. Peritoneal mesothelioma is a rare disorder and no standard of care yet exists for its treatment, so this study was an important attempt to learn more about effective therapies for patients with the disease.

For a full report on the study, please view the article on our website:

About Mesothelioma:
Mesothelioma is a disease caused only by exposure to asbestos. It most commonly affects the pleural surfaces in the chest cavity, where it is known as pleural mesothelioma, but it can also affect the peritoneum (peritoneal mesothelioma), the pericardium (pericardial mesothelioma) and the tunica vaginalis in males (mesothelioma of the tunica vaginalis). Current medical therapies can treat symptoms of the disease and may slow its progress, but a cure has not yet been found and the disease is almost always fatal. Mesothelioma has robbed thousands of families of life and loved ones and, tragically, its worldwide incidence is on the rise.

About is one of the web's leading sources of information about mesothelioma. The website features information on the various forms of the disease and its common symptoms, as well as information on cutting-edge mesothelioma treatments and therapies. also features patient profiles, biographic and contact information for mesothelioma specialists throughout the country and a daily blog where the latest research on asbestos and mesothelioma is reported on.

The information contained in is provided as a public service for informational purposes only and is not intended to provide medical advice. Only a doctor can provide medical advice or specific diagnostic and treatment information. Questions about individual health should only be discussed with a physician. is sponsored by Belluck & Fox.

About Belluck & Fox
Belluck & Fox, LLP is a nationally recognized law firm that represents individuals with asbestos and mesothelioma claims, as well as victims of crime, medical malpractice, motorcycle crashes, lead paint and other serious injuries. We provide personalized and professional representation and have won over $175 million in compensation for our clients and their families. Partner Jordan Fox has been named to the Best Lawyers in America and to Super Lawyers and on two separate occasions his verdicts were featured as the National Law Journal's Largest Verdict of the Year. Partner Joseph W. Belluck is a Super Lawyer and has prosecuted numerous cases involving injuries from asbestos, defective medical products, tobacco and lead paint, including a recent asbestos case that settled for over $12 million.

With offices in New York City, Albany, Woodstock and Rochester, few other law firms represent individuals in as many courthouses in New York State. We have represented clients in Buffalo, Rochester, Syracuse, Albany, Utica, Watertown, Rome, Ticonderoga, Seneca Falls, Niagara Falls, Troy, Corning, Elmira, Binghamton, Glens Falls, Poughkeepsie, Kingston, Waterloo, Ithaca, Jamestown, Olean, Plattsburgh, Massena, Schenectady and Oswego.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Joseph W. Belluck
Visit website